24小时热门版块排行榜

返回列表

zlwcw

木虫 (著名写手)

应助: 1 (幼儿园)
金币: 2021.1
散金: 225
红花: 8
帖子: 1274
在线: 219.7小时
虫号: 530429
注册: 2008-03-21
性别: GG
专业: 代谢性疾病药物药理

[交流] 百时美施贵宝公司与清华大学达成新的战略合作伙伴关系已有3人参与

Bristol-Myers Squibb has entered into a new multi-year strategic partnership with the Tsinghua University of Beijing.

The pharmaceutical company will be funding research efforts at the Chinese university's school of life sciences, focusing on the identification of novel targets in oncology and immunoscience.

In addition, the partnership will focus on structural biology research, a process involving mapping the 3D protein structure of biological molecular targets to serve as the basis for future drug discovery projects.

This will be the first time that Bristol-Myers Squibb has entered into a China-based discovery collaboration, with the resulting research to benefit patients around the world.

Dr Francis Cuss, senior vice-president for research at Bristol-Myers Squibb, said: "We are delighted to be working with Tsinghua University, a world-renowned and highly esteemed research-based academic institution with expertise in target identification and structural biology that will support the discovery of new medicines."

Earlier this year, the firm announced a new alliance with the Duke Translational Medicine Institute, which will initially focus on the development of an idiopathic pulmonary fibrosis drug.
2012年5月16日，百时美施贵宝（Bristol-Myers Squibb）公司已与清华大学达成战略合作伙伴关系。

百时美施贵宝公司将资助清华大学生命科学学院的研究工作，重点在于肿瘤学及免疫学领域新靶标的鉴定。此外，此次合作关系将重点放在结构生物学研究。结构生物学涉及描绘生物分子靶标的3D蛋白结构，为未来的药物开发项目奠定基础。

这是施贵宝公司首次与我国的科研机构达成合作伙伴，该项研究合作的结果将造福世界各地的患者。

施贵宝公司研发高级副总裁Francis Cuss博士称："我们很高兴能与清华大学展开合作。清华大学是享誉全球及备受尊敬的专业学术机构，其在靶标识别及结构生物学方面的专业知识将有助于新药物的探索和发现。"

今年早些时期，施贵宝公司宣布与杜克大学转化医学研究所达成新的联盟，合作最初将专注于特发性肺纤维化药物的开发。（生物谷bioon.com）

回复此楼